Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04227938 · ClinicalTrials.gov registry record · Phase 1
ALPN-101 in Steroid-resistant or Steroid-refractory Acute GVHD
A Phase 1 study, sponsored by Alpine Immune Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT04227938: Clinical Trial Phase 1 study, sponsored by Alpine Immune Sciences.
NCT04227938 is a Phase 1 study that was terminated before completion, run by Alpine Immune Sciences. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04227938, a Phase 1 study, was terminated before completion, sponsored by Alpine Immune Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The Balance study will assess the safety, tolerability, and efficacy of an investigational drug called ALPN-101 in adults with steroid-resistant or steroid-refractory acute graft versus host disease (aGVHD).
Primary Outcome
The incidence, severity, and seriousness of AEs, including dose-limiting toxicities, assessed by CTCAE
Interventions
- DRUG ALPN-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-05-11 |
| Est. Completion | 2020-05-21 |
| Phase | Phase 1 |
Why NCT04227938 stopped before completion
NCT04227938 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which ALPN-101 is the first listed.
NCT04227938 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04227938 about?
NCT04227938 is a clinical study titled "ALPN-101 in Steroid-resistant or Steroid-refractory Acute GVHD". The Balance study will assess the safety, tolerability, and efficacy of an investigational drug called ALPN-101 in adults with steroid-resistant or steroid-refractory acute graft versus host disease (aGVHD).
What is the current status of trial NCT04227938?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2020-05-11. Estimated completion is 2020-05-21.
What interventions are being tested in trial NCT04227938?
The interventions under investigation include: ALPN-101 (DRUG).
Who is sponsoring clinical trial NCT04227938?
This trial is sponsored by Alpine Immune Sciences, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04227938's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI